Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Active not recruiting 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Dermatologic 3Thoracic 2Gastrointestinal 2Sarcoma 1Other solid neoplasm 1Head & Neck 1Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 31Colorectal Neoplasms 18Carcinoma, Hepatocellular 18Stomach Neoplasms 12Esophageal Squamous Cell Carcinoma 12Squamous Cell Carcinoma of Head and Neck 9Neoplasm Metastasis 9Advanced Solid Tumor 9Lung Neoplasms 7Head and Neck Neoplasms 7Rectal Neoplasms 5Esophageal Neoplasms 5Small Cell Lung Carcinoma 4Neoplasms 4Nasopharyngeal Carcinoma 4Melanoma 4Solid Tumor 3Lymphoma, Follicular 3Colonic Neoplasms 3Carcinoma, Renal Cell 3Biliary Tract Neoplasms 3Adenocarcinoma 3Triple Negative Breast Neoplasms 2Recurrence 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Extranodal NK-T-Cell 2Lymphoma 2Hodgkin Disease 2

Interventions

Nivolumab 70pembrolizumab 69cabozantinib 46Ipilimumab 38Specimen Handling 33Magnetic Resonance Spectroscopy 33lenvatinib 26Axitinib 25belzutifan 21Sunitinib 18Biopsy 15Radiosurgery 14CTLA-4 Antigen 13atezolizumab 12Everolimus 10pazopanib 8fludarabine 8avelumab 8Bevacizumab 8toripalimab 7cemiplimab 7Nephrectomy 7Immunoglobulin G 7Cyclophosphamide 7aldesleukin 6Standard of Care 6Radiotherapy 6Blood Specimen Collection 6spartalizumab 5palbociclib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × tislelizumab × 1 year × Clear all
NCT05661955 2026-05-11

A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.

BeOne Medicines

Phase 1/2 Active not recruiting
113 enrolled
DermatologicGenitourinary

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Melanoma

NCT05238883 2025-11-21

A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

HiFiBiO Therapeutics

Phase 1 Active not recruiting
72 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmSarcomaThoracic

Testicular Germ Cell Tumor, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Melanoma, Mesothelioma, Sarcoma, Stomach Neoplasms

NCT05789069 2025-11-21

A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

HiFiBiO Therapeutics

Phase 1 Active not recruiting
83 enrolled
DermatologicGastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡